Fugro N.V.: 1 director

A director at Fugro N.V. maiden bought 2,000 shares at 11.390EUR and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...

Tessenderlo Feedback 1H results conference call

Below are the highlights from the conference call. Tessenderlo's 1H results positively surprised, with adj EBITDA up 8% y/y to 163.4m, which was 19% better than our forecast and 12% above consensus. The company reiterated its broad FY25 guidance range, with consensus currently at the midpoint of the range whilst KBCS estimates are at the low end of the guidance range (and will be upped somewhat). The company is using its solid balance sheet and FCF to buy back own shares. We consider valuation t...

Benelux Morning Notes

AEGON: Addition of €200m to existing SBB, considering US domicile, results mixed. Alfen: 19% EBITDA cut, mid-point new 2026 guidance. Flow Traders: Positive volumes, negative volatility. Kinepolis: Strong profit beat on better operating leverage, higher ticket and ITS per visitor. Recticel: Peer Rockwool 2Q25 results. Tessenderlo: Solid 1H25 beat, guidance maintained. VGP: Strong results, more news on JVs to come

Morning Notes : AGN NA, DSFIR NA, KIN BB, TESB BB, VGP BB, ALFEN NA

: AGN NA, DSFIR NA, KIN BB, TESB BB, VGP BB, ALFEN NA

Tessenderlo FIRST LOOK: 1H adj EBITDA +8%, FY guidance maintained

Tessenderlo's 1H results positively surprised, with adj EBITDA up 8% y/y to 163.4m, which was 19% better than our forecast and 12% above consensus. The company reiterated its broad FY25 guidance range, with consensus currently at the midpoint of the range whilst KBCS estimates are at the low end of the guidance range (and will be upped somewhat). The company is using its solid balance sheet and FCF to buy back own shares. We consider valuation to be attractive enough from maintaining our Accumul...

2Q25 Results: Telenet, VodafoneZiggo, Virgin Media O2/A strategic pivo...

The 2Q25 earnings of VodafoneZiggo, Telenet and Virgin Media O2[de] continue to look soft. Interestingly, a network carve-out in the UK now seems off the table, while Liberty Global is working to unlock the intrinsic value of its separate businesses through divestitures, as they have done with Sunrise. Nevertheless, 2Q25 performance was underwhelming and our conviction to buy or sell the notes is low. Despite stable QoQ leverage, we see limited value in current spreads. Nevertheless, there is st...

Tessenderlo/Model update ahead of 1H25/BUY

We update our model to reflect recent macro and FX trends as well as Tessenderlo's 2025F guidance. We lower our target price to €30 per share from €32 previously, mainly as a result of our lower estimates. We stick to our BUY on valuation grounds.

Galapagos Receives FDA RMAT designation for GLPG5101 in r/r MCL

Galapagos announced that the FDA has granted RMAT designation to GLPG5101 (CD19- CAR-T) to treat relapsed/refractory mantle cell lymphoma (r/r MCL). This is based on the strong data that GLPG5101 has demonstrated in the MCL cohort in the phase 1/2 (ATLANTA-1) trial in r/r NHL, and comes with a number of potential benefits including eligibility for accelerated approval, and could further support external discussions as Galapagos explores strategic alternatives for the cell therapy business. Accum...

Benelux Morning Notes

Belgian telcos: Telenet small positive net adds, good financials, guidance up. Kinepolis: US Cinemark strong, 5% growth in US tickets, consumption per visitor. KPN: VodafoneZiggo 2Q25 very weak, guidance maintained. PostNL: 2Q25 beats underlying slightly; FY25 guidance reiterated, EU court appeal

Galapagos NV: 1 director

A director at Galapagos NV bought 95,856 shares at 33.260USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

Galapagos FIRST LOOK: Post 1H25 1-1 mgt. call key takeaways

Galapagos reported 1H25 results today and we had the opportunity to catch up with management including new CEO Henry Gosebruch and new CFO Aaron Cox. We summarise our main takeaways in this note.

Galapagos : Acceleration of losses reflecting the direct impact of the...

Morning Notes : AALBa NA, BSIB NA, GLPGa NA

: AALBa NA, BSIB NA, GLPGa NA

Galapagos Uneventful 1H25 results, updates to come with 3Q25 results

Galapagos reported uneventful 1H25 results with € 3.1b in cash, though no FY25 cash burn guidance was provided (previously € 175-225m) and an update is expected with the 3Q25 results. In the pipeline, strategic alternatives continue to be explored for the cell therapy business and more information is expected with the 3Q25 results. € 37 TP maintained, though we update our rating to Accumulate (from Buy) given the absence of near-term triggers.

Galapagos : Une accélération des pertes reflétant l’impact direct de l...